期刊文献+

Circulating biomarkers for nonfunctional gastroenteropancreatic neuroendocrine neoplasm:Where do we stand?

下载PDF
导出
摘要 Gastroenteropancreatic neuroendocrine neoplasms(GEP-NENs) encompass a heterogeneous group of tumors associated with variable presentations, growth rates, and prognoses. The majority of GEP-NENs are nonfunctional, and their diagnosis remains challenging given the often subtle and variable clinical manifestations of these tumors. As a consequence, GEP-NENs are often recognized at an advanced stage; indeed, most patients with nonfunctional GEP-NENs exhibit metastatic disease at diagnosis. Lack of treatment options as well as limitations in currently available imaging modalities and biomarkers make it challenging to manage NENs. Thus, novel biomarkers are needed to provide high sensitivity and specificity for minimum disease detection and to predict treatment efficacy and prognosis. Although tissue-based biomarker data can provide such information, circulating biomarkers such as NETests, circulating tumor cells, and micro RNAs, are superior owing to their easy accessibility and the ability for repeated real-time sampling. Gastroenteropancreatic neuroendocrine neoplasms(GEP-NENs) encompass a heterogeneous group of tumors associated with variable presentations, growth rates, and prognoses. The majority of GEP-NENs are nonfunctional, and their diagnosis remains challenging given the often subtle and variable clinical manifestations of these tumors. As a consequence, GEP-NENs are often recognized at an advanced stage; indeed, most patients with nonfunctional GEP-NENs exhibit metastatic disease at diagnosis. Lack of treatment options as well as limitations in currently available imaging modalities and biomarkers make it challenging to manage NENs. Thus, novel biomarkers are needed to provide high sensitivity and specificity for minimum disease detection and to predict treatment efficacy and prognosis. Although tissue-based biomarker data can provide such information, circulating biomarkers such as NETests, circulating tumor cells, and micro RNAs, are superior owing to their easy accessibility and the ability for repeated real-time sampling.
作者 Panpan Zhang Lin Shen Panpan Zhang;Lin Shen(Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of GI Oncology,Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China)
出处 《Oncology and Translational Medicine》 2017年第1期15-19,共5页 肿瘤学与转化医学(英文版)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部